ClinicalTrials.gg
RecruitingNCT06970106PYC-001-CL-102Updated Jun 29, 2026

Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)

A Phase 1/2 interventional study of PYC-001 in OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy and Hereditary Optic Atrophies, sponsored by PYC Therapeutics. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by PYC Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to gather safety data and determine the optimal dosing regimen for PYC-001 in participants with confirmed OPA1 mutation-associated ADOA. Approximately 18 participants from Australia, New Zealand, and other APAC countries are expected to be enrolled, depending on safety review committee (SRC) throughout the course of the study.

Participants may be assigned to any of the following:

  1. A single 60ug dose of PYC-001
  2. Three doses of 10ug PYC-001 at an interval of 8 weeks
  3. Three doses of 10ug PYC-001 at an interval of 12 weeks
  4. Three doses of 30ug PYC-001 at an interval of 8 weeks
  5. Three doses of 30ug PYC-001 at an interval of 12 weeks

    Following completion of the 4 week safety review of the single 60ug of PYC-001 cohort, and if the 60 μg dose level is deemed safe by the SRC, the following cohorts will also be available:

  6. Three doses of 60ug PYC-001 at an interval of 12 weeks
Read the detailed description

This is a phase 1b open-label, randomized, single and repeat dose study to evaluate the safety and tolerability of IVT administered PYC-001 in participants with confirmed OPA1 mutation-associated ADOA.

The primary objective of this study is to gather safety data and determine the optimal dosing regimen for PYC-001.

The exploratory objectives of this study include evaluating the ocular structural and functional changes following multiple doses of IVT administered PYC-001. The PK profile of PYC-001 following multiple doses will also be assessed.

In this open-label study, PYC-001 will be injected in a single eye and ocular safety will be assessed in both eyes.

02

Conditions studied

  • OPA1 Gene Mutation
  • Autosomal Dominant Optic Atrophy
  • Hereditary Optic Atrophies
  • Kjer Optic Atrophy
03

In context

Lead sponsor

PYC Therapeutics is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must give written before any study-related activity is carried out
  2. Adult males and females, aged 18 years and above at screening;
  3. ≥18.0 and ≤35.0 kg/m2
  4. Have a recent (within five years) genetic diagnosis of OPA1 mutation-associated (haploinsufficiency) ADOA and/or confirmed diagnosis during pre-screening or screening, as determined by the PI.
  5. Treatment naïve participants with best-corrected visual acuity (BCVA) of between ≤20/40 (≤70 Early Treatment of Diabetic Retinopathy Study [ETDRS] letters) and ≥20/200 (≥35 ETDRS letters).
  6. Treatment Naïve participants with mild to moderate visual field loss and retinal nerve fiber layer (RNFL) loss in the study eye only as determined by the Spectralis Glaucoma Module Premium Edition (GMPE) RNFL \& visual field structure function data (map)
  7. Medically healthy (in the opinion of the PI), as determined by pre-study medical history
  8. Female participants must be of non- or if female participants are of childbearing potential, they must:

    1. Have a negative pregnancy test at the screening visit and on study Day -1;
    2. Agree not to attempt to become pregnant or donate ova from signing of the consent form until at least 130 days after final IVT dose administration of PYC-001;
    3. Agree to use adequate
  9. Male participants must:

    1. Agree not to donate sperm
    2. If engaging in sexual intercourse with a female partner who could become pregnant, agree to use adequate contraception
    3. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, agree to use a condom
  10. Willing and able to comply with all study assessments and protocol schedule/ restrictions

Exclusion criteria

Exclusion Criteria:

  1. Participant has a known allergy to PYC-001 or any of its ;
  2. Demonstrated co-morbidities, which, in the opinion of the PI, would interfere with the participant's ability to participate in the study and/or confound study outcomes;
  3. Females who are breastfeeding or planning to breastfeed;
  4. Based on recent genetic testing, the participant has mutations in genes that cause ADOA, other than OPA1 (for example in case of dominant negative ADOA and ADOA Plus) or has other pathological variants that result in an ADOA-like optic atrophic phenotype or other pathologic genetic findings indicating presence of additional confounding ocular diseases based on comprehensive genetic screening.
  5. Have received any prior cell or gene therapy for a retinal condition, excluding participation in study PYC-001-101;
  6. Within three months prior to study Day -1, have undergone any vitreoretinal surgery or any other ocular surgery in the study eye.
  7. Within three months prior to study Day -1, have placement of an Ozurdex® implant. T
  8. Within three years prior to study Day -1, have placement of Retisert® of Iluvien® implants.
  9. Have ocular media opacity or poor pupillary dilation prohibiting quality ophthalmic evaluation or photography, ;
  10. Macular edema (intraretinal, sub-retinal or other fluid) in the study eye requiring treatment.
  11. History of recurrent uveitis (idiopathic or immune-related) or active ocular inflammation;
  12. Have used within 30 days of the Screening visit or is using any drug or over-the-counter drug such as Idebenone, Vitamin B6, Vitamin B12, A decision will be made on a case-by-case basis by the PI in consultation with the Sponsor.
  13. Over-the-counter drugs like CoQ10 and other Nutraceutical usage will require a by five half-lives prior to baseline visit.
  14. Have a recent history (\<6 months) of or current excessive recreational drug or alcohol use, in the opinion of the PI.
  15. Positive alcohol breath test as assessed at screening, and on study Day -1 and study Day 1;
  16. Positive urine drugs of abuse as assessed at screening and on study Day -1 and study Day 1;
  17. Any retinal pathology other than ADOA or any other condition or prior therapy that in the opinion of the PI would make the volunteer unsuitable for this study
  18. Presence of illness or pathology that, per investigator, include symptoms and/or the associated treatments that can alter visual function including current ocular infection.
  19. Positive test for , or C virus;
  20. Clinically significant findings in clinical chemistry, hematology, coagulation and urinalysis tests at screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Single Dose of 60ug

    A single dose of 60ug of PYC-001 administered intravitreally

    Drug: PYC-001

  • Experimental
    Cohort 2: 10ug of PYC-001, 8 weeks

    Up to 12 doses of 10ug PYC-001, administered intravitreally in 8 weeks interval.

    Drug: PYC-001

  • Experimental
    Cohort 3: 10ug of PYC-001, 12 weeks

    Up to 12 doses of 10ug PYC-001, administered intravitreally in 12 weeks interval

    Drug: PYC-001

  • Experimental
    Cohort 4: 30ug of PYC-001, 8 weeks

    Up to 12 doses of 30ug PYC-001, administered intravitreally in 8 weeks interval

    Drug: PYC-001

  • Experimental
    Cohort 5: 30ug of PYC-001, 12 weeks

    Up to 12 doses of 30ug PYC-001, administered intravitreally in 12 weeks interval

    Drug: PYC-001

  • Experimental
    Cohort 6: 60ug of PYC-001, 12 weeks

    Following SRC, Single dose participant can continue to receive Up to 12 doses of 60ug PYC-001, administered intravitreally at 12 weeks interval; alternatively, treatment naive participants can be enrolled (once SRC is complete) to receive up to 12 doses

    Drug: PYC-001

Interventions

  • DrugPYC-001

    PYC-001 is a peptide-phosphorodiamidate morpholino oligonucleotide administered intravitreally

06

What researchers measure

Primary outcomes

  1. [All Cohorts] Number of participants experiencing treatment emergent adverse events

    The incidence, type, severity, and relationship of treatment emergent ocular and non-ocular adverse events and treatment-emergent Serious Adverse Events will be recorded. An AE is any untoward medical occurrence in a clinical study participant that either occurs during the study or, if present predose, worsens during the study, and which does not necessarily have to have a causal relationship with the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease associated with study participation, whether or not considered related to the study treatment.

    Time frame: Up to 164 weeks

  2. [All Cohorts] Changes from baseline in vital signs (heart rate)

    Time frame: Up to 164 weeks

  3. [All Cohorts] Changes from baseline in vital signs (systolic and diastolic blood pressure)

    Time frame: Up to 164 weeks

  4. [All Cohorts] Changes from baseline in vital signs (tympanic temperature)

    Time frame: Up to 164 weeks

  5. [All Cohorts] Changes from baseline in vital signs (respiratory rate)

    Time frame: Up to 164 weeks

  6. [All Cohorts] Change from baseline in white blood cells (WBC), platelets, white blood cell count with differential neutrophil count, eosinophil count, basophil count, lymphocyte count, monocyte count

    All measured in 10x\^9L

    Time frame: Up to 164 weeks

  7. [All Cohorts] Change from baseline in red blood cells

    Units x 10\^12L

    Time frame: Up to 164 weeks

  8. [All Cohorts] Change from baseline in hemoglobin and mean corpuscular hemaglobin concentration

    Units: grams per liter (g/L)

    Time frame: Up to164 weeks

  9. [All Cohorts] Change from baseline in mean corpuscular volume and mean platelet volume

    measured in femtoliter (fL)

    Time frame: Up to 164 weeks

  10. [All Cohorts] Change from baseline in hematocrit

    Units: litres per litre (L/L)

    Time frame: Up to 164 weeks

  11. [All Cohorts] Change from baseline in mean corpuscular hemoglobin

    Units: picograms (pg)

    Time frame: Up to 164 weeks

  12. [All Cohorts] Change from baseline in neutrophils, lymphocytes, monocytes, eosinophils, basophils and reticulocyte count

    Units: %

    Time frame: Up to 164 weeks

  13. [All Cohorts] Change from baseline in Alanine Transaminase, Alkaline Phosphatase, Aspartate aminotransferase, Creatine Phosphokinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase, Amylase and Lipase

    Units: units/Liter (U/L)

    Time frame: Up to 164 weeks

  14. [All Cohorts] Change from baseline in Bilirubin (total, direct and indirect) and creatinine

    Units: micromoles per liter (mcmol/L)

    Time frame: Up to 164 weeks

  15. [All Cohorts] Change from baseline in protein, albumin, globulin and fibrinogen

    Units:grams per liter (g/L)

    Time frame: Up to 164 weeks

  16. [All Cohorts] Change from baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Bicarbonate, Calcium, Magnesium, Phosphorous, Total Cholesterol, Triglyceride, HDL, LD. Uric Acid and Glucose

    Units: millimoles per liter (mmol/L)

    Time frame: Up to 164 weeks

  17. [All Cohorts] Change from baseline in Anion Gap

    Units: milliequivalents per liter (mEq/L)

    Time frame: Up to 164 weeks

  18. [All Cohorts] Change from baseline in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Up to 164 weeks

  19. [All Cohorts] Change from baseline in Prothrombin Time and Partial Thromboplastin Time, Activated (APTT)

    Time frame: Up to 164 weeks

  20. [All Cohorts] Change from baseline in Prothrombin Time (INR)

    Time frame: Up to 164 weeks

  21. [All Cohorts] Change from baseline in urinalysis (Protein, glucose, ketones, blood, bilirubin, leucocyte esterase and nitrites

    Presence (positive, negative, trace) captured

    Time frame: Up to 164 weeks

  22. [All Cohorts] Change from baseline in urinalysis (pH)

    Time frame: Up to 164 weeks

  23. [All Cohorts] Change from baseline in urinalysis (specific gravity)

    Time frame: Up to 164 weeks

Secondary outcomes

  1. [All Cohorts] Change from Baseline in Best Corrected Visual Acuity (BCVA)/ High Contrast Visual Acuity (HCVA) and Low Contrast Visual Acuity (LCVA) scores

    Early Treatment Diabetic Retinopathy Study (ETDRS) optotypes used, letter score will be captured for BCVA/HCVa and LCVA.

    Time frame: Up to 164 weeks

  2. [All Cohorts] Change from Baseline in Visual field sensitivity by photopic static perimetry

    Time frame: Up to 164 weeks

  3. [All Cohorts] Change from Baseline in posterior eye health by fundus examination using ultrawide fundoscopy

    Time frame: Up to 164 weeks

  4. [All Cohorts] Change from Baseline in Color vision

    Time frame: Up to 164 weeks

  5. [All Cohorts] Change from Baseline in Contrast sensitivity by Pelli Robson chart

    Time frame: Up to 164 weeks

  6. [All Cohorts] Change from Baseline in Multifocal visual evoked potential OR Full field electroretinogram

    Time frame: Up to 164 weeks

  7. [All Cohorts] Change from Baseline in Retinal nerve fiber layer (RNFL) by spectral domain optical coherence tomography

    Time frame: Up to 164 weeks

  8. [All Cohorts] Change from Baseline for Ganglion Cell Layer (GCL) thickness determined by Spectral domain optical coherence tomography

    Time frame: Up to 164 Weeks

  9. [All Cohorts] Change from Baseline for Bruch's membrane opening (BMO) disc size, as determined by spectral domain optical coherence tomography

    Time frame: Up to 164 weeks

  10. [All Cohorts] Change from Baseline in Mitochondrial function test via flavoprotein fluorescence

    Time frame: Up to 164 weeks

  11. [Repeat Dose Cohorts] Plasma concentrations of PYC-001 following multiple dose intravitreally administered PYC-001

    Time frame: Up to 164 weeks

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Oct 2029, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 14, 2025
StartActual
Sep 30, 2025
Primary completionEst.
Oct 2029
CompletionEst.
Nov 2029
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06970106
Lead sponsor
PYC Therapeutics
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Sep 30, 2025
Primary completion
Oct 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Jun 29, 2026

Study contacts

Jessica Stevenson
Contact
adoa@pyctx.com
+61 8 6151 0992

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion